Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
HC Wainwright & Co. Maintains Buy on Portage Biotech, Lowers Price Target to $21
HC Wainwright & Co. analyst Robert Burns maintains Portage Biotech (NASDAQ:PRTG) with a Buy and lowers the price target from $22 to $21.
Oppenheimer Maintains Outperform on Portage Biotech, Lowers Price Target to $18
Oppenheimer analyst Matthew Biegler maintains Portage Biotech (NASDAQ:PRTG) with a Outperform and lowers the price target from $26 to $18.
HC Wainwright & Co. Maintains Buy Rating for Portage Biotech: Here’s What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Portage Biotech (NASDAQ:PRTG) and lower its price target from $32.00 to $22.00.
Shares of Portage Biotech are trading down 3.11% over the last 24 hours, at $7.05 per share.
HC Wainwright & Co. Maintains Buy on Portage Biotech, Lowers Price Target to $22
HC Wainwright & Co. analyst Robert Burns maintains Portage Biotech (NASDAQ:PRTG) with a Buy and lowers the price target from $32 to $22.
Portage Biotech Provides Research And Development Update; Highlights Its Clinical Strategy For Its Adenosine And iNKT Platforms; Development Goals Are Focused On Producing Phase 1b/Phase 2 Efficacy Readouts In Multiple Tumor Types Over The Next Two Yea…
--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms--
--Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next
Portage Biotech: Q1 Earnings Insights
Portage Biotech (NASDAQ:PRTG) reported its Q1 earnings results on Monday, August 29, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform
Portage Biotech Inc (NASDAQ:PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now…